Table 3 Oncological outcomes

Patients

n (%)

37.00 (100.00)

12.00 (100.00)

25.00 (100.00)

STSMs

n (%)

37.00 (100.00)

12.00 (100.00)

25.00 (100.00)

Positive LNs

n (%)

6.00 (16.22)

1.00 (8.33)

5.00 (20.00)

0.641^a

No. positive LNs

mean (SD)

0.32 (0.85)

0.33 (1.15)

0.32 (0.69)

0.463^b

median (range)

0.00 (0.00–4.00)

0.00 (0.00–3.00)

0.00 (0.00–4.00)

Clinical recurrence free within 1 year

n (%)

0.646^a

 No

31.00 (86.11)

11.00 (91.67)

20.00 (83.33)

 Yes

5.00 (13.89)

1.00 (8.33)

4.00 (16.67)

Pathological_type

n (%)

> 0.999^a

 Urothelial carcinoma

36.00 (97.30)

12.00 (100.00)

24.00 (96.00)

 Squamous cell carcinoma

1.00 (2.70)

0.00 (0.00)

1.00 (4.00)

Pathological T-stage

n (%)

0.443^a

 pT1

11(29.7)

3.00 (25.00)

8.00 (32.00)

 pT2

16(43.2)

6.00 (50.00)

10.00 (40.00)

 pT3

6(16.2)

3.00 (25.00)

3.00 (12.00)

 pT4

4(10.8)

0.00 (0.00)

4.00 (16.00)

pN stage

n (%)

0.808^a

 pN0

31(83.8)

11.00 (91.67)

20.00 (80.00)

 pN1

2(5.4)

0.00 (0.00)

2.00 (8.00)

 pN2

4(10.8)

1.00 (8.33)

3.00 (12.00)

pM stage

n (%)

 pM0

0(0)

0(0)

0(0)

Pathological grading

n (%)

0.659^a

 Low grade

7(18.9)

3.00 (25.00)

4.00 (16.00)

 High grade

30(81.1)

9.00 (75.00)

21.00 (84.00)

Angiolymphatic invasion

n (%)

0.149^a

 Negative

24.00 (64.86)

10.00 (83.33)

14.00 (56.00)

 Positive

13.00 (35.14)

2.00 (16.67)

11.00 (44.00)

Recurrence rate

n (%)

0.224^a

 No

28.00 (77.78)

11.00 (91.67)

17.00 (70.83)

 Yes

8.00 (22.22)

1.00 (8.33)

7.00 (29.17)

Secondary neoplasm

n (%)

0(0)

0(0)

0(0)